USD10
Actions CGON
À propos de CG OncologyCG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
USD10
Actions CGON
À propos de CG OncologyCG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Statistiques
FENÊTRE DE TRADING
Fermé
OUVRE À
24 mars at 13:30 UTC+0
Capitalisation boursière
5,49 Md $US
PRIX D'OUVERTURE
Données insuffisantes
BAS (1 an)
14,80 $US
ÉLEVÉ (1 an)
69,35 $US
BAS (24 h)
63,97 $US
ÉLEVÉ (24 h)
66,55 $US
Volume (24 h)
1,22 k $US
99,94 %
Historique des prix
Time | Price | Change |
|---|---|---|
Aujourd'hui | Données insuffisantes | Données insuffisantes |
1 jour | 65,08 $US | |
1 semaine | 65,70 $US | |
1 mois | 58,30 $US | |
1 an | 27,54 $US |